BPC
IRON icon

Bryce Point Capital’s Disc Medicine IRON Stock Holding History

Bryce Point Capital’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$259K Buy
+3,912
New +$233K 0.32% 148

Other funds holding IRON

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bryce Point Capital's IRON Position: Q3 2025 in Review

Bryce Point Capital opened a new position in Disc Medicine (IRON) in Q3 2025: 3,912 shares worth $259K. The stake represents 0.32% of the portfolio and ranks #148 among its holdings.

168 funds tracked by Wall St. Rank hold IRON as of Q3 2025.

  • Bryce Point Capital held 3,912 shares of Disc Medicine worth $259K as of Q3 2025.
  • Disc Medicine was a new Bryce Point Capital position in Q3 2025.
  • Disc Medicine made up 0.32% of Bryce Point Capital's portfolio in Q3 2025, its #148 holding.
  • 168 funds tracked by Wall St. Rank held Disc Medicine as of Q3 2025.

Based on Bryce Point Capital's 13F filing for Q3 2025, filed 6 Nov 2025.